Bambusa Therapeutics Reports Positive Early Phase 1 Results for BBT001 in Atopic Dermatitis
BOSTON, July 27, 2026 Bambusa Therapeutics announced encouraging preliminary proof-of-concept results from its ongoing global Phase 1 clinical trial...
Bambusa Therapeutics
Advertisement
Kalohexis Shares 710GO Data Supporting Durable Weight Loss
NORTHBROOK, Ill., July 15, 2026 Kalohexis, Inc., a clinical-stage biotechnology company developing innovative therapies for metabolic diseases, has unveiled...
Bambusa Reports Promising BBT002 Data for COPD Therapy
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary multiple ascending dose (MAD) Phase 1 clinical data for...
Akeso Enrolls First Patient in AK138D1-Ivonescimab Breast Cancer Trial
HONG KONG, June 15, 2026 Akeso, Inc. has announced the enrollment of the first patient in the Phase Ib/II...
Bambusa Therapeutics Reports Positive Phase 1 BBT002 Data at EAACI 2026
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of...
Advertisements
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
Advertisement
